Trials / Completed
CompletedNCT00938730
A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation
A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study To Investigate the Safety and Tolerability of YM150 in Subjects With Non-Valvular Atrial Fibrillation and to Compare the Safety and Tolerability With Warfarin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,280 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the optimal daily dose and dose regimen of YM150 in subjects with non-valvular atrial fibrillation (NVAF), primarily based on safety and tolerability data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YM150 | oral |
| DRUG | Warfarin | oral |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2009-07-14
- Last updated
- 2011-01-20
Locations
170 sites across 23 countries: Australia, Austria, Bulgaria, Czechia, Estonia, France, Germany, Hungary, India, Israel, Japan, Malaysia, Netherlands, Philippines, Poland, Russia, Slovakia, South Africa, South Korea, Spain, Thailand, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00938730. Inclusion in this directory is not an endorsement.